A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants with Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Trial Identifier: V940-009
Sponsor: MSD
Collaborator:
ModernaTX, Inc
Start Date: October 2024
Primary Completion Date: May 2033
Study Completion Date: January 2038
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English

Trial Locations

Country Location
Argentina, Buenos Aires CABA, Buenos Aires, Argentina, C1431FWO
Argentina, Santa Fe Rosario, Santa Fe, Argentina, S2001SBK
Australia, Queensland Southport, Queensland, Australia, 4215
Canada, QC Montréal, QC, Canada, H4A 3J1
Chile, Valparaiso Vina del Mar, Valparaiso, Chile, 2520598
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Jerusalem, N/A, Israel, 9103102
Israel, N/A Jerusalem, N/A, Israel, 9112001
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Korea, Republic of, Kyonggi-do Suwonsi, Kyonggi-do, Korea, Republic of, 16247
Taiwan, Tainan Tainan, Taiwan, 704
United Kingdom, London, City of London, London, City of, United Kingdom, EC1A 7BE
United States, ID Post Falls, ID, United States, 83854
United States, MO Osage Beach, MO, United States, 65065
United States, TN Knoxville, TN, United States, 37916